Gourin Christine G, Moretz William H, Weinberger Paul M, Xia Zhong-Sheng, Liu Zhongmin, Terris David J, Adam Bao-Ling
Center for Biotechnology and Genomic Medicine, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912-4060, USA.
Arch Otolaryngol Head Neck Surg. 2007 Nov;133(11):1125-30. doi: 10.1001/archotol.133.11.1125.
To determine the sensitivity and specificity of surface-enhanced laser desorption and ionization time-of-flight mass spectrometry (SELDI-TOF-MS) assay for head and neck squamous cell carcinoma (HNSCC) disease surveillance.
The SELDI-TOF-MS serum protein profiles of patients with HNSCC were analyzed to determine the sensitivity and specificity of the SELDI assay for HNSCC detection following definitive treatment.
Academic research.
Thirty-two patients with previously untreated HNSCC.
Serum samples were collected prospectively at 3-month intervals following treatment during a 24-month follow-up period.
Ninety-three serum samples were analyzed.
The SELDI-TOF-MS identified protein peaks in the range of 0 to 100 kDa. Classification tree analysis based on peak expression distinguished pretreatment from 6-month posttreatment samples with 75.0% sensitivity and 87.5% specificity. Samples collected at 3 months following treatment did not significantly differ from pretreatment samples. Serum samples from patients who were disease free at 6 months or longer following treatment differed from matched pretreatment samples by the overexpression of a protein peak at 6495 Da, while serum samples from patients with recurrence differed from matched pretreatment samples by the underexpression of a protein peak at 4493 Da.
Proteomic analysis of serum protein profiles distinguishes pretreatment and posttreatment samples from patients with HNSCC with a high degree of sensitivity and specificity. After 6 months, serum protein profiles seem to have distinct differences in peak expression based on disease status. Further investigation of the clinical usefulness of this technology in HNSCC detection and surveillance is warranted.
确定表面增强激光解吸电离飞行时间质谱(SELDI-TOF-MS)检测对头颈部鳞状细胞癌(HNSCC)疾病监测的敏感性和特异性。
分析HNSCC患者的SELDI-TOF-MS血清蛋白谱,以确定SELDI检测在根治性治疗后对HNSCC检测的敏感性和特异性。
学术研究。
32例未经治疗的HNSCC患者。
在24个月的随访期内,治疗后每隔3个月前瞻性收集血清样本。
分析93份血清样本。
SELDI-TOF-MS鉴定出0至100 kDa范围内的蛋白峰。基于峰表达的分类树分析区分治疗前和治疗后6个月的样本,敏感性为75.0%,特异性为87.5%。治疗后3个月收集的样本与治疗前样本无显著差异。治疗后6个月或更长时间无疾病的患者的血清样本与匹配的治疗前样本相比,6495 Da处的蛋白峰过表达,而复发患者的血清样本与匹配的治疗前样本相比,4493 Da处的蛋白峰低表达。
血清蛋白谱的蛋白质组学分析以高度的敏感性和特异性区分HNSCC患者的治疗前和治疗后样本。6个月后,血清蛋白谱似乎根据疾病状态在峰表达上有明显差异。有必要进一步研究该技术在HNSCC检测和监测中的临床实用性。